Ind-Swift surges on talk of atorvastatin API supply deal with Ranbaxy
This article was originally published in Scrip
Executive Summary
Shares of Ind-Swift Laboratories were on a roll on Indian bourses on 14 September following reports that the firm was in discussions to supply atorvastatin active pharmaceutical ingredient (API) to Ranbaxy for the latter's cut-price generic version of Pfizer's Lipitor. A US launch of Ranbaxy's product is expected at the end of November this year.
You may also be interested in...
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Need a specific report? 1000+ reports available
Buy Reports